Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Press release

Sensyne Health’s MagnifEye AI software product gains MHRA ‘Authorisation of Special Use’ in connection with DHSC COVID-19 Self-Test Lateral Flow Device

May 7, 2021

Oxford, U.K. 07 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the UK Clinical AI company, announces that its MagnifEye software application that uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted Authorisation of Special Use by the Medicines & Healthcare products Regulatory Agency (“MHRA”).

The authorisation is specifically for the use of MagnifEye with the Innova COVID-19 lateral flow self-test kit, the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.  The Innova lateral flow test was used as it is currently the only test to have received temporary MHRA derogation and will continue to be used with MagnifEye under the Authorisation of Special Use.

The Company is also pursuing a wider authorisation for the use of MagnifEye with other manufacturers’ kits and for other medical indications and continues to work closely with its exclusive licence and technology partner, Excalibur Healthcare Services Limited.

Lord (Paul) Drayson PhD FREng, CEO, said:

MagnifEye has demonstrated that it has the potential to play an important role in COVID-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation.  We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”  

Press release

Sensyne Health’s MagnifEye AI software product gains MHRA ‘Authorisation of Special Use’ in connection with DHSC COVID-19 Self-Test Lateral Flow Device

May 7, 2021

Oxford, U.K. 07 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the UK Clinical AI company, announces that its MagnifEye software application that uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted Authorisation of Special Use by the Medicines & Healthcare products Regulatory Agency (“MHRA”).

The authorisation is specifically for the use of MagnifEye with the Innova COVID-19 lateral flow self-test kit, the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.  The Innova lateral flow test was used as it is currently the only test to have received temporary MHRA derogation and will continue to be used with MagnifEye under the Authorisation of Special Use.

The Company is also pursuing a wider authorisation for the use of MagnifEye with other manufacturers’ kits and for other medical indications and continues to work closely with its exclusive licence and technology partner, Excalibur Healthcare Services Limited.

Lord (Paul) Drayson PhD FREng, CEO, said:

MagnifEye has demonstrated that it has the potential to play an important role in COVID-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation.  We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”  

Press release

MagnifEye gains ‘Authorisation of Special Use’

Sensyne Health’s MagnifEye AI software product gains MHRA ‘Authorisation of Special Use’ in connection with DHSC COVID-19 Self-Test Lateral Flow Device

May 7, 2021

Oxford, U.K. 07 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the UK Clinical AI company, announces that its MagnifEye software application that uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted Authorisation of Special Use by the Medicines & Healthcare products Regulatory Agency (“MHRA”).

The authorisation is specifically for the use of MagnifEye with the Innova COVID-19 lateral flow self-test kit, the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.  The Innova lateral flow test was used as it is currently the only test to have received temporary MHRA derogation and will continue to be used with MagnifEye under the Authorisation of Special Use.

The Company is also pursuing a wider authorisation for the use of MagnifEye with other manufacturers’ kits and for other medical indications and continues to work closely with its exclusive licence and technology partner, Excalibur Healthcare Services Limited.

Lord (Paul) Drayson PhD FREng, CEO, said:

MagnifEye has demonstrated that it has the potential to play an important role in COVID-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation.  We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”  

Press release

MagnifEye gains ‘Authorisation of Special Use’

Sensyne Health’s MagnifEye AI software product gains MHRA ‘Authorisation of Special Use’ in connection with DHSC COVID-19 Self-Test Lateral Flow Device

Oxford, U.K. 07 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the UK Clinical AI company, announces that its MagnifEye software application that uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted Authorisation of Special Use by the Medicines & Healthcare products Regulatory Agency (“MHRA”).

The authorisation is specifically for the use of MagnifEye with the Innova COVID-19 lateral flow self-test kit, the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.  The Innova lateral flow test was used as it is currently the only test to have received temporary MHRA derogation and will continue to be used with MagnifEye under the Authorisation of Special Use.

The Company is also pursuing a wider authorisation for the use of MagnifEye with other manufacturers’ kits and for other medical indications and continues to work closely with its exclusive licence and technology partner, Excalibur Healthcare Services Limited.

Lord (Paul) Drayson PhD FREng, CEO, said:

MagnifEye has demonstrated that it has the potential to play an important role in COVID-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation.  We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”  

Arrange to meet us
Press release

MagnifEye gains ‘Authorisation of Special Use’

May 7, 2021

Oxford, U.K. 07 May 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company”), the UK Clinical AI company, announces that its MagnifEye software application that uses AI to automate the accurate reading and analysis of lateral flow diagnostic tests, has been granted Authorisation of Special Use by the Medicines & Healthcare products Regulatory Agency (“MHRA”).

The authorisation is specifically for the use of MagnifEye with the Innova COVID-19 lateral flow self-test kit, the platform originally used to test the MagnifEye technology as part of the NHS Digital pilot study.  The Innova lateral flow test was used as it is currently the only test to have received temporary MHRA derogation and will continue to be used with MagnifEye under the Authorisation of Special Use.

The Company is also pursuing a wider authorisation for the use of MagnifEye with other manufacturers’ kits and for other medical indications and continues to work closely with its exclusive licence and technology partner, Excalibur Healthcare Services Limited.

Lord (Paul) Drayson PhD FREng, CEO, said:

MagnifEye has demonstrated that it has the potential to play an important role in COVID-19 disease surveillance with increased lateral flow test reading accuracy and greater certainty over correct test interpretation.  We believe our technology also demonstrates the value of AI in the analysis of medical images, a field that Sensyne has deep expertise in.”